Skip to main content
. 2013 Apr;83(4):882–893. doi: 10.1124/mol.112.084111

Fig. 7.

Fig. 7.

Simultaneous inhibition of FGFR, ERBB family receptors, and MET leads to greater growth inhibition compared with the double combinations in a subset of HNSCC cell lines. (A) UMSCC25, UMSCC1, and UMSCC25 were treated in triplicate with 0.5 μM AZ8010, 10 nM AZD8931, 0.1 μM PF1066, the respective double combinations, and the triple combination. Growth was measured by clonogenic assay and quantified after 2 weeks. (B) MSK-921 cells were treated in triplicate as in (A). Growth was measured via anchorage independent growth assay. (C) 584-A2 cells were treated in triplicate with 0.1 μM AZ8010, 10 nM AZD8931, 0.1 μM PF1066, the respective double combinations, and the triple combination. Growth was measured after 2 weeks by clonogenic assay. CCL30 cells were treated in triplicate with 0.1 μM AZ8010, 10 nM AZD8931, 0.1 μM PF1066, the respective double combinations, and the triple combination. Growth was measured after 2 weeks using an anchorage independent growth assay. Data are the means and S.E.M. of three independent experiments. Statistical analysis using a two-tailed t test revealed significant differences in growth. ns, not significant. **P < 0.005; ****P < 0.0001.